Which funds bought or sold ELV in Q3 2026?
Elevance Health Inc Formerly. 9 funds bought, 12 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was −$376M. See also what famous investors say about ELV.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- AQR+$542M
- Bank of America+$341M
- Invesco+$324M
- Marshall Wace+$109M
- Northern Trust+$75M
- JennisonNEW+$73M
- Schonfeld+$35M
- Pzena+$3M
- MaverickNEW+$1M
- Millennium−$281M
- Wellington−$271M
- Amundi−$246M
- Goldman Sachs−$231M
- QRT−$220M
- Citadel−$201M
- CPP Investments−$90M
- Oakmark−$57M
- Adage−$46M
- GlenviewOUT−$26M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (9)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| AQR Quant & multi-strategy | Added+328.3% | +$542M | $707M |
| Bank of America Bank & broker | Added+48.6% | +$341M | $1.0B |
| Invesco Asset manager | Added+19.7% | +$324M | $2.0B |
| Marshall Wace Quant & multi-strategy | Added+1331.7% | +$109M | $117M |
| Northern Trust Bank & broker | Added+9.1% | +$75M | $897M |
| Jennison Growth / crossover | New | +$73M | $73M |
| Schonfeld Quant & multi-strategy | Added+1152.4% | +$35M | $38M |
| Pzena Value investor | Added+3.8% | +$3M | $91M |
| Maverick Hedge fund | New | +$1M | $1M |
Sold (12)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Millennium Quant & multi-strategy | Trimmed-99.5% | −$281M | $2M |
| Wellington Asset manager | Trimmed-7.6% | −$271M | $3.3B |
| Amundi Asset manager | Trimmed-38.5% | −$246M | $393M |
| Goldman Sachs Bank & broker | Trimmed-29.6% | −$231M | $549M |
| QRT Quant & multi-strategy | Trimmed-88.3% | −$220M | $29M |
| Citadel Quant & multi-strategy | Trimmed-57.2% | −$201M | $151M |
| CPP Investments Sovereign & pension | Trimmed-34.3% | −$90M | $173M |
| Oakmark Value investor | Trimmed-3% | −$57M | $1.9B |
| Adage Hedge fund | Trimmed-68.9% | −$46M | $21M |
| Glenview Hedge fund | Sold out | −$26M | — |
| Brown Advisory Asset manager | Trimmed-11.5% | −$24M | $183M |
| Baillie Gifford Growth / crossover | Trimmed-4.3% | −$18M | $403M |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.